 
<prompt> National-Level Trends in IPTp 3+ | Percent of women age 15-49 with a live birth in the past two years who, during their last pregnancy, received atleast 3 or more doses of SP/Fansidar who received atleast one dose during an antenatal care visit. | (EDSB-III 2006, 1) (EDSB-IV 2011-2012, 9) (EDSB-V 2017-2018, 13) <response> Only 13% of women age 15-49 with a live birth in the two years before the survey received three or more doses of SP/Fansidar, at least one during an antenatal visit. Coverage of IPTp 3+ increased significantly from 1% in 2006 to 9% in 2011-2012 to 13% in 2017-2018.  